

Research Article

Inhibition of hepatitis C virus internal ribosome entry site-mediated translation by an RNA targeting the conserved III_f domain

C. Romero-López, R. Díaz-González and A. Berzal-Herranz*

Instituto de Parasitología y Biomedicina “López-Neyra”, CSIC, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento s/n, Armilla, 18100 Granada (Spain), Fax: +34–958181632, e-mail: Aberzalh@ipb.csic.es

Received 26 July 2007; received after revision 24 September 2007; accepted 26 September 2007
Online First 15 October 2007

Abstract. Hepatitis C virus (HCV) translation initiation depends on an internal ribosome entry site (IRES). We previously identified an RNA molecule (HH363–10) able to bind and cleave the HCV IRES region. This paper characterizes its capacity to interfere with IRES function. Inhibition assays showed that it blocks IRES activity both *in vitro* and in a human hepatoma cell line. Although nucleotides involved in binding and cleavage reside in separate regions of the inhibitor HH363–10, further analysis demonstrated the strongest effect to be an intrinsic

feature of the entire molecule; the abolishment of either of the two activities resulted in a reduction in its function. Probing assays demonstrate that HH363–10 specifically interacts with the conserved III_f domain of the pseudoknot structure in the IRES, leading to the inhibition of the formation of translationally competent 80S particles. The combination of two inhibitory activities targeting different sequences in a chimeric molecule may be a good strategy to avoid the emergence of resistant viral variants.

Keywords. Aptamer, ribozyme, HCV targeting, RNA-based inhibitors, gene silencing.

Introduction

Hepatitis C virus (HCV) infection affects more than 170 million people worldwide. Current treatments show poor efficacy due to the highly active dynamics of the HCV populations that promote the appearance of drug-resistant variants [1]. This problem, also faced in control of other viral infections, has prompted an intensive search for new drugs and alternative therapeutic strategies. Combination approaches are cur-

rently considered excellent candidates to reduce the chance of viral evasion.

The HCV genome is a 9500-nucleotide (nt)-long (+) single-stranded (ss) RNA molecule. During early viral infection, uncapped viral RNAs initiate their translation using a highly conserved internal ribosome entry site (IRES) located at the 5′ untranslated region (UTR; Fig. 1; [2, 3]), which includes from nt 40 to 372 of the viral genome [4, 5]. It has a complex secondary and tertiary structure that acts as a scaffold for recruiting multiple protein factors during the initiation of translation [6]. This mechanism considerably differs from that used by the cellular capped mRNAs, rendering it a potential candidate for antiviral therapies.

* Corresponding author.

a




Figure 1. The hepatitis C virus (HCV) internal ribosome entry site (IRES) domain and HH363–10. (a) Sequence and secondary structure of the HCV IRES. The ribozyme cleavage site is indicated by an arrow. Nucleotides proposed to interact with HH363–10 are shown in bold and enlarged. Start codon is in italics. (b) Sequence and secondary structure of HH363–10 predicted by experimental constraints and employing Mfold software. Ribozyme HH363 is shadowed. Tertiary contacts predicted by PknotsRG are indicated by dotted lines. G nucleotides accessible to T1 under non-denaturing conditions are indicated by open (low), gray (medium) or filled triangles (high accessibility). Residues in the aptamer domain responsible for the interaction with domain IIIe of the IRES are shown in bold and enlarged. Encircled nucleotides were mutated as indicated to generate the respective inactive variants (HH363 m-10, G₁₄ → A; HH363–10 m, C₄₉ GUA₅₂ → GCAC; HH363 m-10 m, G₁₄ → A and C₄₉ GUA₅₂ → GCAC).




Figure 1. (continued)

The use of RNA molecules as gene inactivation agents is a therapeutic option that has been investigated in depth [7]. Antisense RNAs and siRNAs have been proved to effectively inhibit replication of several viruses, including HCV [8]. These molecules work by sequence complementarity and in many cases viruses promptly escape the treatment [9–13]. Viral targeting with other RNA molecules like ribozymes and aptamers has also been accomplished with different success [8]. In contrast to antisense and siRNAs, aptamers do not operate only by sequence complementarity, but also by the recognition of secondary and tertiary structures. The formation of productive complexes is a major requisite for the correct functioning of aptamers and ribozymes. These features contribute to diminishing the chance of appearance of resistant viral mutants. An additional issue in minimizing the risk of the emergence of escape variants is the use of several inhibitors with different specificities [14–16]. We previously designed a novel combined approach [17]. An *in vitro* selection method was employed to isolate a collection of RNA molecules composed of a hammerhead ribozyme (named HH363) targeting positions 357–369 of the HCV genome, plus an aptamer for the 5'UTR that carries complementary nucleotides to unique sequences in the IRES domain [17]. In the present study, the selected variants have been assayed for their ability to interfere with IRES function. This has allowed the identification of a very potent inhibitor designated as HH363–10, which behaves as an aptamer with complementary sequences to domain IIIIf of

the 5'UTR (Ap10; Fig. 1; [17]). This region participates in the formation of a pseudoknot structure essential for IRES function [18]. It has been proposed that the IIIIf domain interacts with the 40S ribosomal subunit [19, 20] and favors the formation of active translational 80S complexes [21]. This is the first report of an RNA molecule that combine two functional modules that interact with different regions of the HCV IRES, interfering with its function both *in vitro* and in a human liver cell line.

Materials and methods

DNA templates and RNA synthesis. All RNAs were synthesized by *in vitro* transcription and purified as previously described [22]. DNA templates for the HCV-derived RNAs 5'HCV-691 and 5'HCV-691gg were obtained as previously described [17]. The template for RNA 667 was derived from the pcDNA3 vector (Invitrogen) linearized with *Dra*III. The coding sequence for IRES-FLuc was obtained by PCR amplification of the plasmid pCMVCatIREcLuc [17]. The pRLSV40 vector (Promega) was linearized with *Bam*H1 for the synthesis of RLuc mRNA.

The DNA templates for the HH363–10 and HH363 inhibitory RNAs were obtained as described in [17]). The dsDNAs used for the synthesis of Ap10, HH363 m-10, HH363–10 m and HH363 m-10 m were generated by annealing and extension as previously described [23], of oligonucleotide T7GG (5'-taatacgactcactatagg-3') with T7Ap10 (5'-GTAGGATTACGAATCACTCAGAAcctatagtgagtcgtatta-3'), 5'T7HH363 m (5'-TAATACGACTCACTATAGG-GTTCTTTCTGATAAGTCCGTgaggacgaaaggttt-3') with asHH363–10 (5'-GCTGAAAGCTTGGATCCGCTCAGTAGGATTACGAATCACTCAGAAaaaacctttcgtctc-3'), 5'HH363is (5'-TATGAATTCTAATACGACTCACTATAGGGTTCCTTTCTGATGAGTCCGTgaggacgaaaggttt-3') with asHH363–10 m (5'-GCTGAAAGCTTGGATCCGCTCAGTAGGATGTGCAATCACTCAGAAaaaacctttcgtctc-3'), and 5'T7HH363 m (5'-TAATACGACTCACTATAGG-GTTCTTTCTGATAAGTCCGTgaggacgaaaggttt-3') with asHH363–10 m (5'-GCTGAAAGCTTGGATCCGCTCAGTAGGATGTGCAATCACTCAGAAaaaacctttcgtctc-3'); the T7 promoter sequence is underlined; lower case letters indicate the complementary sequences. The plasmid pBSSK was digested with the restriction enzyme *Bam*H1 for the synthesis of RNA₈₀.

The RNA molecules employed in the inhibition assays were obtained using the RiboMAXTM-T7 large-scale RNA production system (Promega); the manufactur-

er's instructions were strictly followed. The transcription mix of IRES-FLuc was supplemented with 200 μ Ci of [α - 32 P]UTP for ribosome assembly assays. During the synthesis of the RNA RLuc, a cap structure was incorporated into its 5' end by adding 5 mM Ribo m⁷G Cap Analog (Promega). The resulting RNAs were purified by phenol extraction and unincorporated nucleotides were removed by two consecutive steps of size exclusion chromatography (Sephadex G-25, GE Healthcare). The amount of RNA was determined by A₂₆₀ measurements, and the extent of protein and carbohydrate/phenolic contaminations was assessed by A₂₆₀/A₂₈₀ and A₂₆₀/A₂₃₀ ratios, respectively. The integrity of the RNA was determined by agarose-formaldehyde gel electrophoresis.

In vitro translation assays. IRES-FLuc and RLuc mRNAs were translated using the Flexi[®] rabbit reticulocyte lysate system (Promega). Reactions proceeded in 6- μ l volumes containing 4 μ l cell extract, 0.1 μ l of the provided amino acid mixture lacking methionine (1 mM), and 0.1 μ l (1.5 μ Ci) of a mixture of L-[35 S]methionine and L-[35 S]cysteine (Redivue Pro-mix L-[35 S] *in vitro* cell labeling kit, GE Healthcare). KCl was supplemented to 100 mM. The RNA templates for the synthesis of either FLuc (IRES-FLuc) or RLuc (RNA RLuc) proteins were added to give a final concentration of 30 ng/ μ l (~40 nM) and 20 ng/ μ l (~60 nM), respectively. Inhibitory RNA concentrations ranging from 10 nM to 5 μ M were assayed. All the RNA molecules were subjected to a denaturing step at 65°C for 10 min and subsequently incubated at 4°C for 15 min prior to their incorporation into the translation mix. Translation proceeded at 30°C for 60 min. Reactions were stopped by cooling on ice and the protein products resolved on 12.5% (w/v) denaturing polyacrylamide gels. Dried gels were scanned in a Phosphorimager (Storm 820, GE Healthcare) and quantified with Image Quant 5.2[®] software (GE Healthcare). The IC₅₀ values were calculated with SigmaPlot 8.02[®] software using the equation $y = y_{\max} / (1 + 10^{(\log IC_{50} - X)})$, where y_{\max} is the maximum percentage of FLuc relative synthesis, IC₅₀ the inhibitor concentration that produces 50% of the maximum observed effect, and X the inhibitor concentration.

IRES cleavage assays. Cleavage experiments proceeded in the presence of rabbit reticulocyte lysates (RRL) under *in vitro* translation reaction conditions. All were performed in the presence of 40 nM 32 P-internally radiolabeled RNA substrate 5'HCV-691. Substrates and inhibitor RNAs were denatured and renatured as described above. After 60 min at 30°C, reactions were stopped on ice and the RNA molecules

were extracted with phenol. Cleavage products were resolved on 4% denaturing polyacrylamide gels, which were subsequently dried and analyzed as above.

RNA-RNA interaction probing assays. RNA probing assays of the complex HH363-10/IRES were performed with 32 P 5' end-labeled inhibitor RNA. Complexes were constructed as described in [17] by incubating 50 fmol 32 P 5'-end-labeled HH363-10 (~500 CPM) with 20 pmol non-labeled HCV RNA. Control reactions were performed in the presence of a non-related RNA (RNA 667). Digestion reactions were initiated by the addition of RNase T1 (0.1 U), RNase A (0.2 ng) or lead acetate (15 mM), and incubated at 4°C for 2 min, 30 min and 20 min, respectively. An equal volume of denaturing loading buffer supplemented with EDTA 100 mM was added, and the products resolved on high resolution denaturing polyacrylamide gels (8–20%). These were dried and scanned as above.

For RNase H-mediated degradation, 50 fmol 32 P 5'-end-labeled 5'HCV-356 (~500 cpm) were incubated with 20 pmol non-labeled inhibitor in the presence of 20 pmol oligonucleotide asIRES305 (5'-ACTCGCA-A-3') or asIRES196 (5'-TATCCAAGA-3'). Complexes were basically formed as described [17]. A final RNase H (USB) concentration of 5 U/ μ l was used to initiate the degradation. Digestion reactions were incubated for 10 min at 37°C and stopped on ice. Specific products were resolved on 6% high resolution denaturing polyacrylamide gels, dried, and scanned as described above.

Ribosome-IRES complex assembly assays. The identification of 48S and 80S particles was essentially performed as described by Ray et al. [24]. Briefly, a concentration of 40 nM of 32 P-internally labeled RNA IRES-FLuc (~200 000 dpm) was incubated with 5 μ M inhibitor RNAs and 5 μ l translation reaction mix containing 4 μ l RRL. To prevent the formation of the 80S particle, the translation mix was supplemented with 2 mM 5'-guanylyl imidophosphate (GMP-PNP, Sigma Aldrich). The reactions were incubated at 30°C for 60 min and stopped on ice. The mixtures were then diluted to 150 μ l with gradient buffer (20 mM Tris-HCl pH 7.5, 100 mM KCl, 3 mM MgCl₂, 1 mM DTT) and loaded onto a continuous 10–30% linear sucrose gradient. Ribosomal complexes were resolved by ultracentrifugation at 30 000 rpm for 4 h in a SW40 Ti rotor. Fractions of 500 μ l were collected from the top of the gradient and their radioactivity was measured using a QuickCount QC-4000/XER Benchtop Radioisotope Counter (Bioscan, Inc.).

Transfection of RNA molecules into Huh-7 cells. Human hepatoma cells (Huh-7) were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and 2 mM L-glutamine (Sigma), at 37°C in a 5% CO₂ atmosphere. At 30 h before transfection, 120 000 cells were seeded onto a 24-well plate. A mix containing 1 µg mRNA IRES-FLuc, 0.5 µg RLuc, 50 µl Opti-MEM® (Invitrogen) and 1.5 µl transfection reagent (TransFectin™, Bio-Rad) was complemented with 50 µl Opti-MEM®, with or without inhibitor RNA. The amounts of inhibitor employed in these assays were established at 0.7, 1.4, 2.7, 4 and 5.4 µg. The total amount of RNA was the same for all transfections (7 µg); this was achieved by complementing with a non-related 80-nt long RNA molecule (RNA₈₀). RNA molecules were denatured, and then renatured, before transfection as above. The lipid-RNA complex was added to the Huh-7 cells and incubated for 18 h at 37°C [25]. *Firefly* and *Renilla* luciferase activities were determined using the Dual-Luciferase™ reporter assay system (Promega).

Results

***In vitro* inhibition of IRES-dependent translation by a collection of chimeric RNAs.** We previously described the isolation by *in vitro* selection of a collection of 30 RNA molecules that specifically target the HCV IRES [17]. All the selected variants were classified into seven families defined by common sequence motifs. One representative of each group was analyzed for its ability to interfere with IRES function in coupled transcription-translation systems. A significant inhibitory activity was detected for the seven tested molecules [17].

To further survey the potential IRES-inhibition function of each selected variant and to exclude any nonspecific effect over transcription, *in vitro* translation assays of monocistronic IRES-FLuc and cap-RLuc mRNAs have been performed using RRL in the presence of the different inhibitor RNAs. IRES activity was measured as the synthesis of FLuc protein and compared to the levels of RLuc, which is translated in a cap-dependent manner. All the molecules inhibited IRES function at a concentration of 5 µM, some of them by as much as 90% (Fig. 2). The difference in the experimental approach (translation instead of transcription-translation) might explain the apparent discrepancies in the observed inhibition data presented here and those previously published [17]. No significant effect was seen on cap-dependent translation (<5%, data not shown) for any of the assayed molecules at the concentration tested, indi-

cating a selective inhibition of IRES function. Since all the RNA molecules shared the HH363 domain, presumably both the targeting site of the aptamer and the structure of the whole inhibitory molecule are associated with the potency of each inhibitor.




Figure 2. *In vitro* inhibition of IRES-dependent translation by the selected variants. The bar chart shows the reduction in FLuc synthesis achieved for each inhibitor RNA at a concentration of 5 µM, normalized with respect to the cap-dependent translation of RLuc mRNA. Values are referred to those obtained in the absence of inhibitor, and are the mean of at least three independent assays.

HH363–10 potently interferes with IRES-dependent translation *in vitro*. We focused on HH363–10, which strongly blocked IRES-dependent translation by up to 90% (Fig. 2). The aptamer sequence contains a motif complementary to the highly conserved domain III_f of the HCV 5'UTR (Fig. 1; [17]), suggesting it to be a possible interaction site. This observation led us to study in detail its activity in *in vitro* translation assays. Several concentrations of HH363–10 were tested, ranging from a molar ratio IRES-FLuc:HH363–10 of 4:1 to 1:125. Strong, dose-dependent inhibition of IRES-dependent translation was observed, with an IC₅₀ value of 150 nM (Fig. 3 and Table 1). Further, at the lowest concentration of the inhibitor tested, a significant reduction in the FLuc levels was achieved (around 20%). This effect was specific for IRES-dependent translation, since the synthesis of RLuc protein was not affected even at the highest concentrations assayed (<5%, data not shown). To corroborate the specificity of HH363–10 for the HCV IRES, a control experiment was performed in which the synthesis of FLuc protein was mediated by the EMCV IRES and normalized with respect to RLuc levels. No significant changes in IRES activity were detected in the presence of HH363–10 (Fig. 3), validating its potential as a specific HCV IRES inhibitor.

Table 1. IC₅₀ values for the different inhibitory RNAs.

Inhibitor	IC ₅₀ (μM) ^a	Relative FLuc synthesis ^b
HH363–10	0.15 ± 0.04	11.22 ± 2.77
Ap10	1.95 ± 0.25	30.76 ± 11.60
HH363	3.46 ± 0.32	42.22 ± 6.32
HH363+Ap10	1.75 ± 0.41	32.39 ± 5.31

^a IC₅₀ values were derived from the equation $y = 100/(1 + 10^{(\text{LogIC}_{50} - X)})$.

^b Data correspond to the highest concentration of inhibitor tested. Values are the mean of at least three independent trials.




Figure 3. Specific *in vitro* inhibition of IRES function by HH363–10. The plot shows the reduction in FLuc synthesis normalized with the levels of RLuc protein. The IRES activity obtained at each concentration of inhibitor is represented as the percentage of the control reaction in the absence of HH363–10. Data were fitted to a non-linear regression curve to determine the IC₅₀ value and are the mean of four independent experiments.

The contribution of the two activities (cleavage by HH363 and binding by Ap10) to the inhibitory capacity of the chimeric molecule was further analyzed. Although they both clearly reduced FLuc levels on their own in a dose-dependent manner, their action was significantly less than that exerted by the entire HH363–10 molecule at every assayed concentration (Fig. 3 and Table 1). A fall in inhibitory activity was also observed (as well as a 12-fold increase in the IC₅₀ value) when both HH363 and Ap10 were simultaneously added to the translation reaction. This indicates that the combination of the two inhibitory domains in a single molecule is required to reach the strongest inhibition.

Cleavage of RNA IRES by HH363–10. The capacity of HH363–10 for processing IRES RNA was previously analyzed *in vitro* in the absence of any protein

factor. A molecule containing the first 691 nt of the HCV-1b genome (5'HCV-691; [17]), comprising the whole IRES to allow ribosome assembly and translation [4], was specifically cleaved at the expected site (Romero-López et al., unpublished data). We wanted to explore the HH363–10 capacity to process the HCV IRES in the presence of translation factors. For this purpose, 40 nM internally radiolabeled 5'HCV-691 RNA was incubated with different amounts of HH363–10 in RRL (see Materials and methods). The proportion of the specific cleavage products increased with increasing amounts of the catalytic RNA, showing a concentration-dependent effect (Fig. 4). Cleavage activity was compared with that of HH363. It showed a slight reduction in the amount of the reaction products in comparison to the chimeric inhibitor (Fig. 4). The improvement in the processing efficiency of HH363–10 in RRL with respect to HH363 may partially reflect the enhancement of the inhibition detected for the chimeric inhibitor.

5'HCV-691 cleavage by HH363-10 or HH363 in RRL




Figure 4. Cleavage of IRES RNA in rabbit reticulocyte lysates (RRL). The graph shows the fraction of the internally radiolabeled 5'HCV-691 RNA substrate processed by different concentrations of either HH363–10 (open circles) or HH363 (filled circles) in the presence of RRL.

Identification of the interacting sites between HH363–10 and the IRES region. We previously identified a sequence within the aptamer, A₄₆UUC-GUAA₅₃, complementary to the IRES III_f domain (Fig. 1; [17]), suggesting its involvement in the interaction with the IRES. Secondary structure analysis and experimental mapping of the residues involved in the interaction was undertaken to validate this hypothesis.

We initially determined the interacting sequence in the IRES region. For this, a 5'-end radiolabeled RNA




Figure 5. Probing assays of the IRES/HH363–10 complex. (*a, b*) Autoradiographs of the RNase H probing assays for 5'HCV-356 with the oligonucleotide asIRES305 (*a*) or asIRES196 (*b*). An amount of 50 fmol of the ^{32}P 5' end-labeled substrate was incubated with (+) or without HH363–10 in the presence of the probe oligonucleotide. Digestion reactions were initiated by the addition of 15 U RNase H and extended up to 10 min. Specific cleavage products were resolved on a 6% high resolution denaturing polyacrylamide gel and are indicated by an arrow. T1L, T1 cleavage ladder. (*c*) The fraction of RNase H cleavage product at different concentrations of HH363–10 is represented.

containing the full 5'UTR was used as a substrate (5'HCV-356; [17]). RNase H probing assays were performed using a 9-mer DNA oligonucleotide, asIRES305, complementary to the loop of domain III_f (see Materials and methods). A specific RNase H cleavage product with the expected length was identified (305 nt; Fig. 5a). Increasing amounts of HH363–10 promoted a significant and dose-dependent reduction in the amount of the degradation product (Fig. 5a,c). This indicates that domain III_f is involved in the binding between the chimeric inhibitor and the IRES. No effect on the RNase H cleavage pattern was observed when a DNA oligonucleotide complementary to positions 196–204 of the HCV genome was used in the presence of HH363–10 (asIRES196; Fig. 5b,c), demonstrating the specificity of the interaction.

RNase and lead probing assays were subsequently performed to analyze the secondary structure of

HH363–10 and to identify the residues involved in the association to domain III_f. The inhibitor RNA was 5' end-labeled with ^{32}P and incubated with a molar excess of a non-related RNA (RNA 667). Partial digestion with nucleases (RNase T1 and RNase A) and lead was subsequently performed. Cleavage mainly occurred at specific single-stranded positions (G nucleotides for RNase T1 probing, C or U residues for RNase A reactions and any nucleotide for lead treatments). The degradation pattern of HH363–10 was used for secondary structure predictions using Mfold software [26]. This showed the exposure of nucleotides A₄₆UUCGUAA₅₃ in an apical loop (Fig. 1b, Fig. 6). Further *in silico* structural analyses with the PknotsRG program predicted the formation of an intramolecular pseudoknot involving the nucleotides A₄₆–G₅₀ and C₆₃–U₆₇ (Fig. 1b, Fig. 6).

The results were compared with those in the presence of the IRES to map the residues involved in the




Figure 6. Secondary structure analysis of HH363-10 and identification of the interacting residues with the IRES. Left panel: ³²P 5' end-labeled HH363-10 was partially digested with RNase T1, RNase A or Pb²⁺, either in the absence (-) or presence (+) of the substrate RNA 5'HCV-691gg. Right panel: A more detailed view of the cleavage pattern for the aptamer domain. Residues participating in the pseudoknot structure are indicated by an asterisk. The arrows show nucleotides G₄₁A_G₄₃. T1L, T1 cleavage ladder. OH, alkaline ladder.

interaction. RNA 5'HCV-691gg was used as a substrate. This extends to nt 691 of the HCV-1b genome sequence, but contains two substitutions (U₃₆₂→G and

C₃₆₃→G) that completely abolish cleavage by the catalytic domain HH363 [27, 28]. The results showed nucleotides G₄₅-C₄₉ to now be clearly resistant to

cleavage (Fig. 6), suggesting their involvement in the interaction of HH363–10 with the IRES. Further, residues C₆₃–U₆₇ showed greater sensitivity to the hydrolytic reagents in the presence of the substrate 5'HCV-691gg. This was in good agreement with the formation of an intramolecular pseudoknot structure in the inhibitor.

These results confirm the initial hypothesis that the III_f domain is the interaction site for HH363–10. To our knowledge, this is the first report describing an RNA aptamer targeting the HCV IRES pseudoknot motif.

HH363–10 prevents the assembly of the 80S ribosomal complex. Domain III_f of HCV IRES has been suggested a crucial motif for the recruitment of the 40S ribosomal subunit in the formation of the 48S particle. It is also reported to be involved in the subsequent structural RNA IRES rearrangements that finally lead to the formation of an active 80S translational complex [19, 29, 30]. The effect of HH363–10 on HCV IRES-mediated ribosome assembly was therefore examined. For this, *in vitro* translation reactions containing ³²P-labeled mRNA IRES-FLuc were performed in the presence or absence of a 125-fold molar excess of HH363–10. The 48S and 80S particles were analyzed by sucrose density gradient ultracentrifugation (see Materials and methods). After fractionation, they were detected as two different and well-defined peaks when no inhibitor was added (Fig. 7). Experimental conditions were established to reproducibly achieve efficient formation of the 48S and 80S complexes in the absence of inhibitor. The addition of HH363–10 reduced the formation of the 80S complex, whereas the 48S particle was clearly produced (Fig. 7). These data were confirmed in subsequent independent assays (data not shown). A similar result was obtained when reactions were incubated with GMP-PNP, a non-hydrolysable GTP analog that blocks the progression of a translation initiation complex at the 48S particle stage (Fig. 7). Similarly, an evident reduction in 80S complex accumulation was detected in the presence of Ap10 (Fig. 7), while no significant changes were observed when HH363 was present (Fig. 7). These observations suggest that the prevention of 80S particle formation is related to the inhibition exerted by HH363–10 and Ap10; this inhibition is explained by their binding to the III_f domain.

Inhibition of IRES function by HH363–10 in a human liver cell line. The effect of HH363–10 on IRES function in cell culture was also examined. A mixture of the IRES-FLuc and cap-RLuc transcripts was co-transfected with HH363–10 into a hepatocellular




Figure 7. HH363–10 and Ap10 prevent the assembly of the 80S ribosomal particle. Sucrose gradient sedimentation profiles of ³²P-internally labeled IRES-FLuc mRNA incubated in RRL in the absence and presence of a 125-fold molar excess of inhibitor RNAs (HH363–10, Ap 10 or HH363) or 2 mM of GMP-PNP. Filled circles, control reaction profile; open circles, sedimentation profile with the inhibitor. In all cases, the percentage disintegrations are represented against the corresponding gradient fraction number. The 48S and 80S complexes are indicated. Fractions were collected from the top downwards.

carcinoma cell line (Huh-7) that supports efficient HCV replication. A dose-dependent study was performed to determine the activity of the inhibitor. HH363–10 appeared as an effective and specific inhibitor of IRES-dependent translation, reducing FLuc activity by up to 50% at 300 nM (Fig. 8) without affecting to that shown by RLuc (<5%; data not shown).

Since the strongest inhibitory effect resides in the complete molecule, a collection of mutants was constructed to further study the contribution of the cleavage and binding activities to the inhibitory function of HH363–10 (Fig. 1b). This included a catalytically non-active derivative (HH363 m-10), a null variant for the interaction site in the aptamer (HH363–10 m), and a completely inactive molecule containing both modifications (HH363 m-10 m; Fig. 1b). These mutations involve a small number of changes in the nucleotide sequence, but they entail a complete loss of function. Modifications in the




Figure 8. Inhibition of IRES-dependent translation by HH363–10 in Huh-7 cells. Huh-7 cells were co-transfected with different amounts of inhibitor RNAs and 1.5 μ g of a mix containing the transcripts IRES-FLuc and RLuc. The collection of mutants was obtained by the introduction of variations in HH363–10 nucleotide sequence as indicated in Figure 1. IRES function is measured as the activity of FLuc protein and referred to that obtained for RLuc. Luciferase activity in the control reactions was established as 100%. Data points are the mean of three independent experiments.

catalytic core led to a full loss of cleavage activity and mutations in the aptamer domain completely abolished association with the IRES (data not shown). Inhibition assays showed that functionality in cells was also severely affected by these mutations. Single mutants mildly inhibited IRES-dependent translation, whereas no inhibitory effect was observed for the HH363 m-10 m construct. This result suggests that the strongest inhibitory activity is an intrinsic feature of the entire HH363–10 molecule combining both activities.

Discussion

The search of novel therapeutic strategies to fight against HCV infection is a major goal. The high variation rate of the viral genome leads to the appearance of populations comprising a spectrum of genomic sequences, in which variants resistant to treatment emerge and contribute to the progression of the disease [1]. In recent years, this has been outlined as the main difficulty in achieving effective therapies and has imposed the necessity of searching new targets. Classical medical approaches targeting essential HCV proteins were considered excellent strategies for a long time. However, mutations conferring

resistance to the treatment have been reported [31]. Efforts were subsequently focused on interfering with highly conserved genomic regions. The great advances in the antisense and siRNA technology prompted the idea of an efficacious therapy in the near future, but in many cases the emergence of resistant viral genomes has been observed for HCV and other viral infections [9–13]. One of the most promising approaches is the specific recognition of highly structured regions in the genomic RNA that importantly retain a conserved sequence and structure and fulfill essential roles in viral translation and replication. They interact with viral and host proteins to carry out these essential functions for the viral maintenance and propagation. This means that the preservation of both primary and secondary structure in those RNA domains is crucial for the conservation of the function [18]. It has been shown that mutations that preserve the secondary structure of the IRES pseudoknot also result in a drastic reduction of the *in vitro* translation efficiency [18]. This is in good agreement with the high sequence conservation observed in this domain among different HCV isolates [32]. In this context, targeting the HCV IRES region is an excellent therapeutic option. The use of ribozymes and aptamers as anti-HCV agents has been extensively reported [8]. Aptamers are considered an excellent option to target highly folded RNA domains [33–35]. In contrast to antisense, for which interaction with complex structured domains is severely restricted, aptamers only require a short stretch of complementary nucleotides in an appropriate structural context to exhibit high affinity and efficiency. Further, the development of combination therapies using antiviral compounds with different specificities would additionally contribute to preventing the emergence of resistant viral pools [1, 14, 15]. The functional characterization of HH363–10, which simultaneously targets two highly conserved regions that are required for the preservation of the IRES activity [18, 36, 37], clearly shows the advantage of combining two inhibitory activities in a single molecule to achieve a strong effect, making our strategy an excellent starting point for the development of new therapeutic tools.

The chimeric RNA HH363–10 strongly inhibited HCV IRES-dependent translation *in vitro*, with an IC_{50} of 150 nM. This value is considerably lower than those reported for a decoy RNA of the stem-loop IIIe-f and for two aptamers of the IRES targeting domains II and III d [24, 33, 35], but is slightly higher than that obtained for an antisense RNA of the III d domain [25]. Since HH363–10 combines two inhibitory activities targeting different domains of the HCV genome, it might result in a more effective anti-HCV agent, although this requires further analysis.

HH363–10 also showed inhibitory activity of the HCV IRES function in a hepatoma cell line, although to a less extent than that seen *in vitro*. This discrepancy has been reported previously [24]. Ray and Das [24] described differences in the inhibition of HCV IRES exerted by small RNAs between *in vitro* and in cell culture experiments. Further, they reported different inhibition levels in two cell lines, HeLa and Huh-7, under similar experimental conditions. It has also been shown that HCV-IRES activity is dependent on the concentration of different translation trans-acting factors. Salt concentrations and the cell cycle phase may influence the HCV-IRES efficiency [38–40]. Differences in inhibition levels can also be the result of the different concentrations of RNA at the right cellular compartment compared to the *in vitro* experiments.

It is noteworthy that the activity of the entire molecule is significantly greater than that measured for the components as independent molecules, HH363 and Ap10. This is consistent with the fact that Ap10 was isolated by the *in vitro* selection process attached to HH363. This, together with the fact that mutations that block either the catalytic activity of the hammerhead ribozyme or the association via the aptamer domain negatively affect the inhibitory capacity of HH363–10, highlights the need for the selected full-length molecule conserving both inhibitory activities if maximum inhibition is to be attained. Although only a low proportion of specific cleavage products are generated by the HH363–10 in RRL, the abolishment of the catalytic activity negatively influences the inhibitory properties of HH363–10, meaning that it contributes to the global inhibitory effect, although to a low extent. Besides the cleavage activity, we cannot discard a possible antisense effect of the catalytic domain. It is also likely that a structural stabilization of the aptamer domain is mediated by the HH363 motif. An improvement in the access to the domain III_f is feasible too. We suggest that the binding of HH363–10 to its target is the key step in its mechanism of action, and that the recognition of the primary, secondary and tertiary structure in the substrate is the essential point to achieve the effectiveness of the inhibitor. None of these possibilities can be ruled out, nor are they mutually exclusive. Other explanations may also be possible. We suggest that the observed inhibition is an intrinsic property of HH363–10, and we cannot define the exact contribution of each activity. It should be also noted that the combination of both inhibitory activities may contribute to reducing the chance of appearance of resistant viral pools.

The results show that domain III_f of the HCV IRES is involved in the interaction with HH363–10 (Fig. 5).

To our knowledge, this is the first report describing an RNA aptamer that specifically interacts with the pseudoknot structure of the HCV IRES. We do not, however, have any information about the nature of this interaction. Nucleotides involved in the association between the inhibitor and the substrate map in apical loops (Figs 5 and 6). It would be therefore plausible that tertiary restricted kissing interactions are established. Since domain III_f participates in the formation of a pseudoknot structure, it seems likely that an additional contribution is required to destabilize this motif and promote the kissing between HH363–10 and the IRES. We hypothesize that residues G₄₁A₄₂G₄₃, complementary to positions 325 to 327 at the 3' end of the pseudoknot structure in the IRES, are working in that way. This is supported by the fact that they show a decrease in their sensitivity to RNase-mediated cleavage in the presence of the substrate RNA (Fig. 6). From a structural and functional point of view, these results are of clear interest. Domain III_f shows strong sequence and structure conservation among different isolates and has an important role in IRES function [18–20]. Distortions in its architecture dramatically affect viral polyprotein translation [18]. The present data show that, as a result of the association of HH363–10 to IRES through the III_f domain, the formation of the 80S particle *in vitro* is almost completely abolished (Fig. 7), which may explain the inhibitory activity of HH363–10. All these features make it an excellent target for HCV inactivation assays.

In summary, the combination of antiviral agents with different specificity and activity in a sole molecule is a novel strategy that could provide a good way of restraining the emergence of resistant variants, and may be extended to other viral infections, such as HIV. The anti-IRES properties shown by HH363–10 both *in vitro* and in cell culture call for its mechanism of action and activity in viral culture systems to be thoroughly investigated. Work in this area is currently underway at our laboratory. Finally, this chimeric molecule has potential as a biochemical tool for studying RNA-RNA interactions and investigating the role of the pseudoknot structure in the HCV cycle.

Acknowledgements. We thank Drs. Alicia Barroso-delJesus, Carlos Briones, Encarnación Martínez-Salas and Jordi Gómez for helpful discussions and suggestions. We also thank Vicente Augustin for excellent technical assistance. This work was supported by grant BFU2006–02568 from the Spanish *Ministerio de Educación y Ciencia* and CTS-233 from the *Junta de Andalucía* to A.B.-H. R.D.-G. was the recipient of a fellowship from the Spanish *Ministerio de Educación y Ciencia*.

- 1 Domingo, E. and Gómez, J. (2007) Quasispecies and its impact on viral hepatitis. *Virus Res.* 127, 131–150.
- 2 Tsukiyama-Kohara, K., Iizuka, N., Kohara, M. and Nomoto, A. (1992) Internal ribosome entry site within hepatitis C virus RNA. *J. Virol.* 66, 1476–1483.
- 3 Wang, C., Sarnow, P. and Siddiqui, A. (1993) Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. *J. Virol.* 67, 3338–3344.
- 4 Reynolds, J. E., Kaminski, A., Carroll, A. R., Clarke, B. E., Rowlands, D. J. and Jackson, R. J. (1996) Internal initiation of translation of hepatitis C virus RNA: The ribosome entry site is at the authentic initiation codon. *RNA* 2, 867–878.
- 5 Wang, T. H., Rijnbrand, R. C. and Lemon, S. M. (2000) Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitis C virus. *J. Virol.* 74, 11347–11358.
- 6 Kieft, J. S., Zhou, K., Jubin, R., Murray, M. G., Lau, J. Y. and Doudna, J. A. (1999) The hepatitis C virus internal ribosome entry site adopts an ion-dependent tertiary fold. *J. Mol. Biol.* 292, 513–529.
- 7 Puerta-Fernández, E., Romero-López, C., Barroso-delJesus, A. and Berzal-Herranz, A. (2003) Ribozymes: Recent advances in the development of RNA tools. *FEMS Microbiol. Rev.* 27, 75–97.
- 8 Romero-López, C., Sánchez-Luque, F. J. and Berzal-Herranz, A. (2006) Targets and tools: Recent advances in the development of anti-HCV nucleic acids. *Infect. Disord. Drug Targets* 6, 121–145.
- 9 Boden, D., Pusch, O., Lee, F., Tucker, L. and Ramratnam, B. (2003) Human immunodeficiency virus type 1 escape from RNA interference. *J. Virol.* 77, 11531–11535.
- 10 Das, A. T., Brummelkamp, T. R., Westerhout, E. M., Vink, M., Madiredjo, M., Bernards, R. and Berkhout, B. (2004) Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. *J. Virol.* 78, 2601–2605.
- 11 Westerhout, E. M., Ooms, M., Vink, M., Das, A. T. and Berkhout, B. (2005) HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. *Nucleic Acids Res.* 33, 796–804.
- 12 Konishi, M., Wu, C. H., Kaito, M., Hayashi, K., Watanabe, S., Adachi, Y. and Wu, G. Y. (2006) siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations. *J. Viral Hepat.* 13, 756–761.
- 13 Sabariego, R., Giménez-Barcons, M., Tápiá, N., Clotet, B. and Martínez, M. A. (2006) Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. *J. Virol.* 80, 571–577.
- 14 Macejak, D. G., Jensen, K. L., Pavco, P. A., Phipps, K. M., Heinz, B. A., Colacino, J. M. and Blatt, L. M. (2001) Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA. *J. Viral Hepat.* 8, 400–405.
- 15 Jarczak, D., Korf, M., Beger, C., Manns, M. P. and Kruger, M. (2005) Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons. *FEBS J.* 272, 5910–5922.
- 16 Korf, M., Jarczak, D., Beger, C., Manns, M. P. and Kruger, M. (2005) Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. *J. Hepatol.* 43, 225–234.
- 17 Romero-López, C., Barroso-delJesus, A., Puerta-Fernández, E. and Berzal-Herranz, A. (2005) Interfering with hepatitis C virus IRES activity using RNA molecules identified by a novel in vitro selection method. *Biol. Chem.* 386, 183–190.
- 18 Wang, C., Le, S. Y., Ali, N. and Siddiqui, A. (1995) An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region. *RNA* 1, 526–537.
- 19 Lytle, J. R., Wu, L. and Robertson, H. D. (2002) Domains on the hepatitis C virus internal ribosome entry site for 40S subunit binding. *RNA* 8, 1045–1055.
- 20 Lyons, A. J., Lytle, J. R., Gomez, J. and Robertson, H. D. (2001) Hepatitis C virus internal ribosome entry site RNA contains a tertiary structural element in a functional domain of stem-loop II. *Nucleic Acids Res.* 29, 2535–2541.
- 21 Fraser, C. S. and Doudna, J. A. (2007) Structural and mechanistic insights into hepatitis C viral translation initiation. *Nat. Rev. Microbiol.* 5, 29–38.
- 22 Barroso-delJesus, A., Tabler, M. and Berzal-Herranz, A. (1999) Comparative kinetic analysis of structural variants of the hairpin ribozyme reveals further potential to optimize its catalytic performance. *Antisense Nucleic Acid Drug Dev.* 9, 433–440.
- 23 Barroso-delJesus, A., Puerta-Fernández, E., Tápiá, N., Romero-López, C., Sánchez-Luque, F. J., Martínez, M.-A. and Berzal-Herranz, A. (2005) Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy. *RNA Biol.* 2, 75–79.
- 24 Ray, P. S. and Das, S. (2004) Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region. *Nucleic Acids Res.* 32, 1678–1687.
- 25 Tallet-López, B., Aldaz-Carroll, L., Chabas, S., Dausse, E., Staedel, C. and Toulmé, J. J. (2003) Antisense oligonucleotides targeted to the domain IIIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent *in vitro* translation. *Nucleic Acids Res.* 31, 734–742.
- 26 Zuker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* 31, 3406–3415.
- 27 Ruffner, D. E., Stormo, G. D. and Uhlenbeck, O. C. (1990) Sequence requirements of the hammerhead RNA self-cleavage reaction. *Biochemistry* 29, 10695–10702.
- 28 Kore, A. R., Vaish, N. K., Kutzke, U. and Eckstein, F. (1998) Sequence specificity of the hammerhead ribozyme revisited; the NHH rule. *Nucleic Acids Res.* 26, 4116–4120.
- 29 Kieft, J. S., Zhou, K., Jubin, R. and Doudna, J. A. (2001) Mechanism of ribosome recruitment by hepatitis C IRES RNA. *RNA* 7, 194–206.
- 30 Ji, H., Fraser, C. S., Yu, Y., Leary, J. and Doudna, J. A. (2004) Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. *Proc. Natl. Acad. Sci. USA* 101, 16990–16995.
- 31 Wohnsland, A., Hofmann, W. P. and Sarrazin, C. (2007) Viral determinants of resistance to treatment in patients with hepatitis C. *Clin. Microbiol. Rev.* 20, 23–38.
- 32 Bukh, J., Purcell, R. H. and Miller, R. H. (1992) Sequence analysis of the 5' noncoding region of hepatitis C virus. *Proc. Natl. Acad. Sci. USA* 89, 4942–4946.
- 33 Kikuchi, K., Umehara, T., Fukuda, K., Hwang, J., Kuno, A., Hasegawa, T. and Nishikawa, S. (2003) RNA aptamers targeted to domain II of hepatitis C virus IRES that bind to its apical loop region. *J. Biochem. (Tokyo)* 133, 263–270.
- 34 Da Rocha Gomes, S., Dausse, E. and Toulme, J. J. (2004) Determinants of apical loop-internal loop RNA-RNA interactions involving the HCV IRES. *Biochem. Biophys. Res. Commun.* 322, 820–826.
- 35 Kikuchi, K., Umehara, T., Fukuda, K., Kuno, A., Hasegawa, T. and Nishikawa, S. (2005) A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIIId. *Nucleic Acids Res.* 33, 683–692.
- 36 Collier, A. J., Tang, S. and Elliott, R. M. (1998) Translation efficiencies of the 5' untranslated region from representatives of the six major genotypes of hepatitis C virus using a novel bicistronic reporter assay system. *J. Gen. Virol.* 79, 2359–2366.
- 37 Piron, M., Beguiristain, N., Nadal, A., Martínez-Salas, E. and Gómez, J. (2005) Characterizing the function and structural organization of the 5' tRNA-like motif within the hepatitis C virus quasispecies. *Nucleic Acids Res.* 33, 1487–1502.

- 38 Kamoshita, N., Tsukiyama-Kohara, K., Kohara, M. and Nomoto, A. (1997) Genetic analysis of internal ribosomal entry site on hepatitis C virus RNA: Implication for involvement of the highly ordered structure and cell type-specific transacting factors. *Virology* 233, 9–18.
- 39 Honda, M., Kaneko, S., Matsushita, E., Kobayashi, K., Abell, G. A. and Lemon, S. M. (2000) Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. *Gastroenterology* 118, 152–162.
- 40 Rijnbrand, R. C. and Lemon, S. M. (2000) Internal ribosome entry site-mediated translation in hepatitis C virus replication. *Curr. Top. Microbiol. Immunol.* 242, 85–116.

To access this journal online:
<http://www.birkhauser.ch/CMLS>
